AC Immune Valuation
| ACIU Stock | USD 2.96 0.10 3.27% |
Based on Macroaxis valuation methodology, the entity appears to be undervalued. AC Immune owns a latest Real Value of $4.4 per share. The recent price of the entity is $2.96. Our model approximates the value of AC Immune from evaluating the entity fundamentals such as Shares Owned By Institutions of 24.80 %, return on asset of -0.22, and Shares Owned By Insiders of 38.00 % as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting AC Immune's valuation include:
Price Book 4.1925 | Enterprise Value | Enterprise Value Ebitda (0.76) | Price Sales 70.4108 | Forward PE 11.236 |
Undervalued
Today
Please note that AC Immune's price fluctuation is unstable at this time. Calculation of the real value of AC Immune is based on 3 months time horizon. Increasing AC Immune's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
AC Immune's intrinsic value may or may not be the same as its current market price of 2.96, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.96 | Real 4.4 | Target 9.11 | Hype 2.97 | Naive 2.83 |
The intrinsic value of AC Immune's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AC Immune's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AC Immune helps investors to forecast how ACIU stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AC Immune more accurately as focusing exclusively on AC Immune's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use AC Immune's intrinsic value based on its ongoing forecasts of AC Immune's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against AC Immune's closest peers.
AC Immune Cash |
|
AC Immune Total Value Analysis
AC Immune is presently forecasted to have valuation of 194.8 M with market capitalization of 307.84 M, debt of 5.43 M, and cash on hands of 154.15 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the AC Immune fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
194.8 M | 307.84 M | 5.43 M | 154.15 M |
AC Immune Investor Information
About 38.0% of the company shares are held by company insiders. The book value of AC Immune was presently reported as 0.8. The company recorded a loss per share of 0.85. AC Immune had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from AC Immune's historical financial statements, AC Immune is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.AC Immune Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AC Immune has an asset utilization ratio of 11.83 percent. This implies that the Company is making $0.12 for each dollar of assets. An increasing asset utilization means that AC Immune is more efficient with each dollar of assets it utilizes for everyday operations.AC Immune Profitability Analysis
Based on the measurements of profitability obtained from AC Immune's financial statements, AC Immune may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess AC Immune's ability to earn profits and add value for shareholders.Net Loss | First Reported 2014-03-31 | Previous Quarter -21.2 M | Current Value -15.9 M | Quarterly Volatility 15.5 M |
For AC Immune profitability analysis, we use financial ratios and fundamental drivers that measure the ability of AC Immune to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well AC Immune utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between AC Immune's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of AC Immune over time as well as its relative position and ranking within its peers.
AC Immune Earnings per Share Projection vs Actual
The next projected EPS of AC Immune is estimated to be -0.142825 with future projections ranging from a low of -0.1785 to a high of -0.1. AC Immune's most recent 12-month trailing earnings per share (EPS TTM) is at -0.85. Please be aware that the consensus of earnings estimates for AC Immune is based on EPS before non-recurring items and includes expenses related to employee stock options.AC Immune Earnings Estimation Breakdown
The calculation of AC Immune's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of AC Immune is estimated to be -0.142825 with the future projection ranging from a low of -0.1785 to a high of -0.1. Please be aware that this consensus of annual earnings estimates for AC Immune is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.18 Lowest | Expected EPS | -0.1 Highest |
AC Immune Earnings Projection Consensus
Suppose the current estimates of AC Immune's value are higher than the current market price of the AC Immune stock. In this case, investors may conclude that AC Immune is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and AC Immune's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 4 | 62.91% | 0.0 | -0.142825 | -0.85 |
AC Immune Ownership Allocation
AC Immune secures a total of 100.6 Million outstanding shares. AC Immune shows tangible amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.AC Immune Profitability Analysis
The company reported the previous year's revenue of 27.31 M. Net Loss for the year was (50.92 M) with loss before overhead, payroll, taxes, and interest of (57.23 M).About AC Immune Valuation
The stock valuation mechanism determines AC Immune's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of AC Immune based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of AC Immune. We calculate exposure to AC Immune's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AC Immune's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -31.7 M | -30.1 M | |
| Pretax Profit Margin | (2.14) | (2.25) | |
| Operating Profit Margin | (2.21) | (2.32) | |
| Net Loss | (2.14) | (2.25) | |
| Gross Profit Margin | (1.48) | (1.56) |
AC Immune Growth Indicators
Investing in growth stocks can be very risky. If the company such as AC Immune does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 99.7 M | |
| Forward Price Earnings | 11.236 |
AC Immune Current Valuation Indicators
AC Immune's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final AC Immune's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as AC Immune, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use AC Immune's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes AC Immune's worth.Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.